Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RIPK1 inhibitor · 1 trial · 1 indication
Maximum plasma concentration
Area under the plasma concentration versus time curve from time zero to the real time last
Area under the plasma concentration versus time curve
| Arm | Type | Description |
|---|---|---|
| SAR443820 | EXPERIMENTAL | Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods |
| Name | Type | Description |
|---|---|---|
| RIPK1 inhibitor | DRUG | Capsule Oral |
Inclusion Criteria: East Asian (Chinese and Japanese) male and/or female participant must be 20 to 55 years of age inclusive, at the time of signing the informed consent. Chinese or Japanese ethnicity, according to the following criteria: Chinese; born in China or ethnic Chinese born outside of C...
RIPK1 inhibitor is an investigational small molecule being developed by Sanofi for use in multiple sclerosis. It is currently in Phase 1 clinical development, with a completed study in healthy subjects. The drug is not yet approved and remains in clinical trials.
RIPK1 inhibitor targets the RIPK1 protein, which is involved in inflammatory and cell death pathways. By inhibiting RIPK1, the drug aims to modulate these pathways, which are relevant to neurological conditions like multiple sclerosis. The exact mechanism is being evaluated in early-stage trials.
RIPK1 inhibitor is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and tolerability in healthy subjects.
RIPK1 inhibitor is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug is still investigational. It has not received regulatory approval and is not yet available for clinical use.
RIPK1 inhibitor has one completed Phase 1 trial, NCT04982991, which was a single ascending dose study in healthy adult Chinese and Japanese female and male participants. The study enrolled 14 participants in the United Kingdom and evaluated the drug in the context of multiple sclerosis.
Yes, RIPK1 inhibitor is also known as SAR443820. The completed Phase 1 trial NCT04982991 was titled 'Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,' confirming the alternative name.